FLINT, Mich. — Diplomat Pharmacy is dispensing a newly approved treatment for chronic hepatitis C. The company on Friday announced that it is now dispensing AbbVie’s Mavyret (glecaprevir and pibrentasvir) tablets.
The drug is indicated to treat patients with all major genotypes of chronic hepatitis C infection with cirrhosis or with compensated cirrhosis. It also is also indicated for adults with Genotype 1 infection who previously have been treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor (but not both).
“We are proud to expand upon Diplomat’s therapy offerings to patients who have been diagnosed with chronic hepatitis C,” said Joel Saban, president of Diplomat. “This valuable treatment option gives more patients the possibility of a life without this serious disease.”